This Medudy course is a video tutorial for physicians on the topic of “Treatment of Advanced Prostate Cancer: The ARANOTE Study.”
Prof. Dr. Peter Hammerer, Chief of the Department of Urology at Braunschweig Municipal Hospital, presents the latest results from the global, randomized, placebo-controlled ARANOTE study, which investigated the efficacy and safety of darolutamide in combination with ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC). He discusses the study design, data on radiological progression-free survival, PSA response, quality of life, and inclusion in the S3 guideline on prostate cancer.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
The course was developed with the kind support of Bayer.
At the end of this training you will know:
- the design and primary endpoints of the global Phase III ARANOTE study.
- the efficacy data for the darolutamide plus ADT dual combination, particularly the significant improvement in radiological progression-free survival (rPFS).
- the results regarding additional endpoints such as PSA response, quality of life (FACT-P), and the safety profile in the ARANOTE study.
- the relevance of the ARANOTE results to the current S3 guideline on prostate cancer for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC).
